Trulieve Cannabis (TRLV) just cleared a fresh milestone, with its shares added to the S&P Total Market Index, S&P Completion Index, and related health care sector indices following its NYSE listing.
For context, Trulieve Cannabis has seen a 47.18% 90 day share price return and a 44.14% year to date share price return. Its 1 year total shareholder return of 64.14% and 3 year total shareholder return of 97.17% point to strong momentum that this index inclusion now brings onto a bigger stage.
Scan how Trulieve Cannabis stacks up against other potential breakout candidates in our hand picked 30 high quality undervalued stocks with resilient balance sheets and solid cash generation profiles.
After a sharp rerating and fresh index inclusion, Trulieve Cannabis still trades at a sizeable discount to both analyst targets and intrinsic estimates. Is that simply opportunity, or is the market pricing in real risks that the valuation work needs to test?
Most Popular Narrative: 31% Undervalued
Against a last close of $12.54, the most followed narrative pegs Trulieve Cannabis at a fair value of $18.18, which implies a sizeable valuation gap that hinges on regulatory change and capital deployment.
A strong cash position of US$353 million against US$290 million in debt and positive free cash flow of US$42 million in the quarter provide room to fund new stores, production upgrades and possible acquisitions, which can influence future revenue and earnings power. Management repeatedly references plans to uplist to a major U.S. exchange, evaluate share buybacks and pursue more active M&A. If these capital allocation choices are timed poorly or regulatory or tax issues constrain flexibility, shareholders could face dilution, higher financing costs or subdued per share earnings despite the current cash balance and free cash flow profile.
See why 7 investors see Trulieve Cannabis as 31% undervalued.
Result: Fair Value of $18.18 (UNDERVALUED)
Still, the Trulieve Cannabis story leans heavily on favorable federal rescheduling outcomes and disciplined capital deployment, and any adverse rulings or mistimed investments could quickly challenge this upside thesis.
Find out about the key risks to this Trulieve Cannabis narrative.
Next Steps
Sentiment around Trulieve Cannabis is clearly split, with both bright spots and clear worries on the table. Move quickly, review the underlying data yourself and pressure test the thesis from both sides by weighing the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Trulieve Cannabis?
If Trulieve Cannabis has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to uncover fresh stocks that fit your own risk and return preferences.
- Target resilient income opportunities by checking out dividend payers that clear strict quality filters through the 7 dividend fortresses.
- Hunt for resilient balance sheets by scanning the list of solid balance sheet and fundamentals (23 results) for businesses with strong financial footing and clean fundamentals.
- Spot tomorrow's potential standouts early by running through the 16 high quality undiscovered gems before the crowd starts paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com